The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurocrine Biosciences, Inc shares valued at $1,157,211 were sold by GORMAN KEVIN CHARLES on May 27 ’25. At $120.38 per share, GORMAN KEVIN CHARLES sold 9,613 shares. The insider’s holdings dropped to 514,596 shares worth approximately $64.08 million following the completion of this transaction.
Also, KEVIN CHARLES GORMAN purchased 9,613 shares, netting a total of over 1,155,290 in proceeds.
Before that, RASTETTER WILLIAM H had sold 30,000 shares from its account. In a trade valued at $3,305,952, the Director traded Neurocrine Biosciences, Inc shares for $110.20 each. Upon closing the transaction, the insider’s holdings decreased to 30,000 shares, worth approximately $4.67 million.
As published in a research note from Needham on April 15, 2025, Neurocrine Biosciences, Inc [NBIX] has been rated up from a Hold to a Buy and the price target has been revised to $138. Analysts at RBC Capital Mkts upgraded the stock from ‘”a Sector perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid April. As of February 11, 2025, Deutsche Bank has initiated its “Hold” rating for NBIX.
Analyzing NBIX Stock Performance
During the last five days, there has been a surge of approximately 1.21%. Over the course of the year, Neurocrine Biosciences, Inc shares have dropped approximately -8.78%. Shares of the company reached a 52-week high of $154.61 on 01/30/25 and a 52-week low of $84.23 on 04/09/25.
Support And Resistance Levels for Neurocrine Biosciences, Inc (NBIX)
According to the 24-hour chart, there is a support level at 123.88, which, if violated, would cause prices to drop to 123.23. In the upper region, resistance lies at 125.58. The next price resistance is at 126.63. RSI (Relative Strength Index) is 64.37 on the 14-day chart, showing neutral technical sentiment.
